Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicenter, Simon Two-Stage Study of Fostamatinib Disodium in Patients With Relapsed or Refractory T-Cell Lymphoma

NCT00798096 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.

NCT NCT00798096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00798096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicenter, Simon Two-Stage Study of Fostamatinib Disodium in Patients With Relapsed or Refractory T-Cell Lymphoma
Lead sponsor
Rigel Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
April 30, 2010
Enrollment
18 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

t cell lymphoma